| Literature DB >> 33794943 |
Ghazal Mousavian1, Nima Ghalekhani1, Fatemeh Tavakoli1, Willi McFarland2, Armita Shahesmaeili1, Heidar Sharafi1,3, Mehrdad Khezri1, Soheil Mehmandoost1, Jasem Zarei1, Hamid Sharifi4, Ali Mirzazadeh1,2.
Abstract
BACKGROUND: Understanding the reasons for loss to follow-up (LTFU) in cohort studies, especially among marginalized groups such as people who inject drugs (PWID), is needed to strengthen the rigor of efficacy trials for prevention and treatment interventions. We assessed the proportion and reasons for loss to follow-up in a recent cohort of PWID enrolled in the southeast of Iran.Entities:
Keywords: Follow-up study; Loss to follow-up; People who inject drugs; Reminder system
Mesh:
Substances:
Year: 2021 PMID: 33794943 PMCID: PMC8017615 DOI: 10.1186/s13011-021-00368-9
Source DB: PubMed Journal: Subst Abuse Treat Prev Policy ISSN: 1747-597X
Fig. 1Reasons for LTFU in a cohort study among PWID in Kerman, Iran
Demographic and behavior characteristics of participants in a cohort study among people who inject drugs in Kerman, Iran
| Characteristics | Total ( | Lost to Follow-up ( | Retained in the cohort | |
|---|---|---|---|---|
| Female | 14 (14.3%) | 6 (12.0%) | 8 (16.7%) | |
| Male | 84 (85.7%) | 44 (88.0%) | 40 (83.3%) | 0.509 |
| Mean ± SD | 39.75 ± 9.64 | 37.96 ± 8.86 | 41.79 ± 10.14 | 0.049 |
| No | 8 (8.2%) | 4 (8.0%) | 4 (8.5%) | 0.927 |
| Yes | 90 (91.8%) | 46 (92.0%) | 43 (91.5%) | |
| Primary or less | 37 (37.8%) | 18 (36.0%) | 19 (39.6%) | 0.619 |
| Some or completed secondary or high school | 53 (54.1%) | 29 (58.0%) | 24 (50.0%) | |
| University | 8 (8.1%) | 3 (6.0%) | 5 (10.4%) | |
| Yes (i.e., married, live with partners) | 14 (14.2%) | 8 (16.0%) | 6 (12.5%) | |
| No (i.e., single, married but live alone, widowed) | 84 (85.8%) | 42 (84.0%) | 42 (87.5%) | 0.621 |
| Unemployed | 23 (23.5%) | 10 (20.0%) | 13 (27.1%) | |
| Employed | 75 (76.5%) | 40 (80.0%) | 35 (72.9%) | 0.408 |
| Under 1,000,000 T (<$100) | 65 (66.3%) | 34 (68.0%) | 31 (64.6%) | 0.303 |
| 1,000,000-4,999,999 T ($100–499) | 31 (31.6%) | 14 (28.0%) | 17 (35.4%) | |
| 5,000,000 T or more (>$500) | 2 (2.1%) | 2 (4.0%) | 0 | |
| No | 77 (79.4%) | 36 (73.5%) | 40 (85.1%) | 0.160 |
| Yes | 20 (20.6%) | 13 (26.5%) | 7 (14.9%) | |
| No recent injection | 15 (15.3%) | 11 (22.5%) | 4 (8.3%) | 0.160 |
| < weekly | 34 (34.7%) | 16 (32.6%) | 18 (37.5%) | |
| < not daily but at least weekly (i.e., weekly) | 22 (22.5%) | 8 (16.3%) | 14 (29.2%) | |
| Daily | 27 (27.5%) | 14 (28.6%) | 12 (25.0%) | |
| No | 35 (35.8%) | 18 (36.0%) | 17 (36.2%) | 0.986 |
| Yes | 63 (64.2%) | 32 (64.0%) | 30 (63.8%) | |
| No | 90 (91.9%) | 44 (88.0%) | 46 (95.8%) | 0.157 |
| Yes | 8 (8.1%) | 6 (12.0%) | 2 (4.2%) | |
| No | 92 (93.9%) | 46 (92.0%) | 46 (95.8%) | 0.429 |
| Yes | 6 (6.1%) | 4 (8.0%) | 2 (4.2%) | |
| No | 57 (58.1%) | 26 (52.0%) | 31 (64.6%) | 0.207 |
| Yes | 41 (41.9%) | 24 (48.0%) | 17 (35.4%) | |
Demographic and behavior characteristics of people who inject drugs who loss to follow-up from a cohort study in Kerman, Iran
| Characteristics | Total LTFU ( | Not found ( | Later Found ( | |
|---|---|---|---|---|
| Female | 6 (12.0%) | 2 (7.4%) | 4 (17.4%) | |
| Male | 44 (88.0%) | 25 (92.6%) | 19 (82.6%) | 0.279 |
| Mean ± SD | 37.96 ± 8.86 | 39.59 ± 9.43 | 36.04 ± 7.91 | 0.719 |
| No | 4 (8.0%) | 1 (3.7%) | 3 (13.1%) | 0.225 |
| Yes | 46 (92.0%) | 26 (96.3%) | 20 (86.9%) | |
| Primary or less | 18 (36.0%) | 11 (40.7%) | 7 (30.5%) | 0.624 |
| Some or completed high school | 29 (58.0%) | 14 (51.9%) | 15 (65.2%) | |
| University | 3 (6.0%) | 2 (7.4%) | 1 (4.3%) | |
| Yes (i.e.,married, live with partners) | 8 (16.0%) | 6 (22.2%) | 2 (8.7%) | |
| No (i.e., single, married but live alone, widowed) | 42 (84.0%) | 21 (77.8%) | 21 (91.3%) | 0.193 |
| Unemployed | 10 (20.0%) | 5 (18.5%) | 5 (21.7%) | |
| Employed | 40 (80.0%) | 22 (81.5%) | 18 (78.3%) | 0.777 |
| Under 1,000,000 T (<$100) | 34 (68.0%) | 20 (74.1%) | 14 (60.8%) | 0.252 |
| 1,000,000-4,999,999 T ($100–499) | 14 (28.0%) | 7 (25.9%) | 7 (30.4%) | |
| 5,000,000 T or more (>$500) | 2 (4.0%) | 0 | 2 (8.8%) | |
| No | 36 (73.5%) | 19 (70.4%) | 17 (77.3%) | 0.586 |
| Yes | 13 (26.5%) | 8 (29. 6%) | 5 (22.7%) | |
| No recent injection | 11 (22.5%) | 7 (25.9%) | 4 (18.2%) | 0.291 |
| < weekly | 16 (32.6%) | 9 (33.4%) | 7 (31.8%) | |
| < not daily but at least weekly (i.e., weekly) | 8 (16.3%) | 6 (22.2%) | 2 (9.1%) | |
| Daily | 14 (28.6%) | 5 (18.5%) | 9 (40.9%) | |
| No | 18 (36.0%) | 7 (25.9%) | 11 (47.8%) | 0.108 |
| Yes | 32 (64.0%) | 20 (74.1%) | 12 (52.2%) | |
| No | 44 (88.0%) | 24 (88.9%) | 20 (87.0%) | 0.834 |
| Yes | 6 (12.0%) | 3 (11.1%) | 3 (13.0%) | |
| No | 46 (92.0%) | 26 (96.3%) | 20 (87.0%) | 0.225 |
| Yes | 4 (8.0%) | 1 (3.7%) | 3 (13.0%) | |
| No | 26 (52.0%) | 14 (51.8%) | 12 (52.2%) | 0.982 |
| Yes | 24 (48.0%) | 13 (48.2%) | 11 (47.8%) | |